hVIVO plc (LON:HVO – Get Free Report) shares fell 6.8% on Thursday . The company traded as low as GBX 19 ($0.24) and last traded at GBX 19.10 ($0.24). 2,518,262 shares traded hands during trading, a decline of 26% from the average session volume of 3,389,765 shares. The stock had previously closed at GBX 20.50 ($0.25).
hVIVO Price Performance
The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61. The firm’s fifty day moving average is GBX 23.39 and its two-hundred day moving average is GBX 26.71. The company has a market cap of £129.95 million, a P/E ratio of 636.67 and a beta of 0.97.
About hVIVO
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
See Also
- Five stocks we like better than hVIVO
- What is the Nikkei 225 index?
- 3 Legacy Tech Companies Reemerging as AI Leaders
- When to Sell a Stock for Profit or Loss
- Analysts’ Favorite Cybersecurity Stocks: 3 Top Picks
- Health Care Stocks Explained: Why You Might Want to Invest
- Analysts Are Bullish: 3 Tech Giants With Upgraded Price Targets
Receive News & Ratings for hVIVO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for hVIVO and related companies with MarketBeat.com's FREE daily email newsletter.
